News
The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...
1don MSN
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...
The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...
Novo Nordisk remains the GLP-1 leader with over 65% market share. Read an in-depth BVO stock analysis and why we rate it as a ...
2d
Investor's Business Daily on MSNNovo Nordisk Slumps As 'Unlawful' Knockoffs Pressure Wegovy, OzempicNovo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, ...
Novo Nordisk hit by slowing Ozempic sales, Tesla shareholders sue Musk over Robotaxi - Stock market news and latest business ...
1d
Futurism on MSNThe Creator of Ozempic Is in Terrible TroubleNovo Nordisk's flagship product is semaglutide. Sold under the names Ozempic and Wegovy, it's one of the leading GLP-1 ...
Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of ...
Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...
The lawsuit, which was filed in U.S. District Court in New Jersey by a single investor, Eric Barta, is a class action on ...
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results